USA flag logo/image

An Official Website of the United States Government

Long Acting Agonists of Adenosine A2a Receptors

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65718
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
HL073587
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADENOSINE THERAPEUTICS, LLC
310 FOURTH STREET NE SUITE 201 CHARLOTTESVILLE, VA 22902
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Long Acting Agonists of Adenosine A2a Receptors
Agency: HHS
Contract: 1R43HL073587-01
Award Amount: $100,885.00
 

Abstract:

DESCRIPTION (provided by applicant): Adenosine is an endogenous nucleoside that exerts its physiological effects through four G-protein coupled receptors A1, A2A, A2B, and A3. Adenosine Therapeutics, LLC is interested in the anti-inflammatory actions mediated by the A2A receptor subtype. A lead compound, ATL-146e, is being developed for coronary artery imaging and has also been shown to be efficacious in several animal models of inflammation. Due to its short half-life, it is not an ideal candidate for chronic inflammatory disorders such as chronic obstructive pulmonary disease (COPD), which would be better treated with a longer-acting compound. Recently, we discovered a novel class of compounds that shows greater potency and duration of action than ATL-146e, but exhibit decreased selectivity. Thus, the goal of this proposal is to synthesize long acting A2A agonists that are potent and selective. We will evaluate these compounds in a functional bioassay that has already been demonstrated to be a useful and efficient tool in predicting a compound's duration of action. As oral dosing may be a preferable route of administration, a secondary goal will be to identify compounds that have oral bioavailability. Finally, we will evaluate standard PK parameters for our best candidates using standard LC/MS protocols that we have developed.

Principal Investigator:

Robert D. Thompson
4349519484
RDT@ADENRX.COM

Business Contact:

Mary Nadler
4342209400
MNADLER@ADENRX.COM
Small Business Information at Submission:

ADENOSINE THERAPEUTICS, LLC
ADENOSINE THERAPEUTICS, LLC 310 4TH ST NE, STE 201 CHARLOTTESVILLE, VA 22902

EIN/Tax ID: 541932209
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No